Mini–Mental State Examination

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the CLEAR MIND Phase 2a Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’s Disease

Retrieved on: 
星期三, 十二月 20, 2023
Quality of life, MRI, Hippocampus, Hypoplastic left heart syndrome, Diffusion MRI, Neuron, Disease, Brain, Incidence, Hypersensitivity, Magnetic resonance imaging, CLEAR, Week, Mini–Mental State Examination, Dementia, Degree, Atrophy, TBV, EKG, DTI, Patient, Thalamus, Magnetic resonance, Safety, Siderosis, HLHS, Alzheimer's disease, Medical imaging

The expanded data set reinforced the earlier top-line findings showing that the primary safety endpoint was met and provided further support for Lomecel-B’s positive benefit/risk profile.

Key Points: 
  • The expanded data set reinforced the earlier top-line findings showing that the primary safety endpoint was met and provided further support for Lomecel-B’s positive benefit/risk profile.
  • Wa’el Hashad, CEO of Longeveron, commented: “These new data support our initial results for CLEAR MIND that we announced in October and provide further validation of both the safety and therapeutic potential of Lomecel-B™ in the treatment of mild Alzheimer’s disease.
  • In addition to these clinical findings, brain imaging showed improvement in brain architecture measured by volumetric MRI and DTI, respectively.
  • Taken together, the Company believes the results of the CLEAR MIND study build a strong foundation for further development in mild Alzheimer's disease patients.

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

Retrieved on: 
星期一, 十一月 6, 2023
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Behavioral neuroscience, Attention, Headache, Incidence, CMAI, Food, Mini–Mental State Examination, DSM-IV codes, Brexpiprazole, OPDC, MD, Psychiatry, Food and Drug Administration Amendments Act of 2007, Deficit spending, Verbal aggression, Dementia, Multimedia, Medicine, Interview, Pneumonia, Somnolence, Lundbeck, Locomotion, Commercialization, JAMA Neurology, Cachexia, Screaming, Caregiver, Passive-aggressive behavior, Aggression, Saint Louis University School of Medicine, MMSE, Heart, Ōtsuka, Akathisia, Contra body movement, Agitation, Medication, Tearing, Anxiety, IPA, Patient, Diagnosis, Disease, Restless, Pharmaceutical industry, Nursing, Birth control

REXULTI is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease.

Key Points: 
  • REXULTI is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease.
  • Participants also required a diagnosis that met The International Psychogeriatric Association’s (IPA) provisional definition of agitation in patients with cognitive impairment or dementia.
  • “Agitation associated with dementia due to Alzheimer’s disease can be very challenging and emotionally distressing for patients and family members caring for them.
  • The trial had high rates of patients completing the trial: 86.8% of the brexpiprazole group and 88.9% of the placebo group.

NKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Retrieved on: 
星期四, 十月 26, 2023
Week, Research, MRI, AD, IND, Mini–Mental State Examination, IV, Glial fibrillary acidic protein, Therapy, CSF, ADAS, Dispute board, Cell, Protein, Clinical trial, PET, Poster, ADAS-Cog, Traffic barrier, Cerebrospinal fluid, NK, Alzheimer's disease, GFAP, MMSE, Classification, Safety, Patient, Medical device, Pharmaceutical industry, Medical imaging, Hospital Angeles Tijuana

SANTA ANA, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (NKGen or the Company), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today presented a poster with Phase I trial data on the use of its investigational NK cell therapy, SNK01, to treat patients with Alzheimer’s disease (AD) at the Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting in Boston, MA.

Key Points: 
  • The severity of AD was based on the baseline Clinical Dementia Rating-Sum of Boxes, or CDR-SB score.
  • The primary endpoint was safety and secondary endpoints included changes in cognitive assessments and biomarker levels.
  • We are very excited to begin this next phase in hopes of establishing an entirely new treatment paradigm for more advanced patients."
  • *Data at Week 22 was only obtained for nine of the ten patients.

Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD

Retrieved on: 
星期二, 十月 24, 2023
AD, Alzheimer's disease, Repeatable Battery for the Assessment of Neuropsychological Status, Vaccine, Meningoencephalitis, Prevalence, Dementia, Research, HIV disease progression rates, Test management, Alzheimer's Association, Cerebral amyloid angiopathy, Mini–Mental State Examination, Disease, Ace, MMSE, Swelling, Assessment, TMT, Emerging technologies, Patient, CAA, Pharmaceutical industry, Medical imaging

Araclon gave a late-breaking presentation at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference.

Key Points: 
  • Araclon gave a late-breaking presentation at the 2023 Clinical Trials on Alzheimer's Disease (CTAD) conference.
  • Data confirm preliminary findings indicating a comparable safety profile between ABvac40 and placebo groups, with similar rates of treatment-emergent adverse events.
  • In addition, volumetric magnetic resonance imaging showed a lesser increase in whole brain atrophy in the ABvac40 group vs placebo.
  • The results reported for ABvac40 to date validate its clinical potential, positioning it as promising therapeutic candidate for early AD treatment.

Altoida's AR-based Digital Cognitive and Functional Assessment Correlates with Standard Neuropsychological Tests in MCI and Healthy Volunteers

Retrieved on: 
星期二, 十月 24, 2023
Data Management, Other Health, Technology, Pharmaceutical, Medical Devices, Seniors, Neurology, Other Technology, Science, Biotechnology, Software, Consumer, Nursing, Health, Research, Digital, DSM-IV codes, Biomarker, Trail Making Test, Test management, Augmented reality, Mini–Mental State Examination, Trail, Free, Machine learning, MMSE, ML, TMT, AR, Patient, DNS, Medical imaging

Digital cognitive assessments offer the potential to facilitate frequent and unbiased measurements of cognitive functional status, without the need of a trained rater,” said Marc Jones, CEO, Altoida.

Key Points: 
  • Digital cognitive assessments offer the potential to facilitate frequent and unbiased measurements of cognitive functional status, without the need of a trained rater,” said Marc Jones, CEO, Altoida.
  • Participants received a neurological evaluation, a neuropsychological test battery, and Altoida’s digital cognitive assessment.
  • The study evaluated the correlation between Altoida’s digital cognitive assessment and standard neuropsychological tests, including: the Mini-Mental State Examination (MMSE) - the Free and Cued Selective Reminding Test (FCSRT) - the Trail Making Test (TMT).
  • Altoida's digital cognitive assessment provides a Digital Neuro-Signature™ (DNS-MCI) score correlated with classical neuropsychological tests that are commonly used as a battery when evaluating patients in clinical research and clinical practice.

NKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023

Retrieved on: 
星期二, 十月 17, 2023
Annual general meeting, Congress, Plasma, Cell, Therapy, Safety, PET, Montreal Cognitive Assessment, ADAS, Patient, ADAS-Cog, MMSE, CSF, Expansion, Poster, Traffic barrier, MRI, AD, Mini–Mental State Examination, NK, Neuroinflammation, WCN, XXVI, Pharmaceutical industry, Medical imaging, QC, Neurology

Severity of AD was based on the baseline Clinical Dementia Rating-Sum of Boxes, or CDR-SB score.

Key Points: 
  • Severity of AD was based on the baseline Clinical Dementia Rating-Sum of Boxes, or CDR-SB score.
  • “The results from our Alzheimer’s trial demonstrate that SNK01 has the potential to cross the blood-brain barrier as evidenced by the CSF biomarker data,” said Paul Y.
  • The pressing need for effective Alzheimer’s treatments cannot be overstated, and we are committed to addressing this healthcare challenge.
  • Based on the CSF biomarker data, intravenous SNK01 appears to cross the blood brain barrier to improve CSF AB42/40 and reduce pTau181 levels.

IntellxxDNA’s Innovative Memory and Genomics Decision-Making Tool Study Gains IRB Approval

Retrieved on: 
星期一, 十月 16, 2023
Research, Pharmaceutical, Consumer, Mental Health, Medical Devices, Genetics, Clinical Trials, Science, Neurology, Seniors, Other Science, Health, Physician, Hope, SCI, Intelligence, Dementia, MOCA, Alzheimer's disease, Mini–Mental State Examination, MMSE, IRB, MCI, Subjective, CDS, CNS, Genomics, Patient, Medical device, Nursing, Birth control, Memory

Signifying a new era in cognitive health research, IntellxxDNA™ is proud to announce its IRB approval for the GPS-MEM Study: A Precision Study of Memory.

Key Points: 
  • Signifying a new era in cognitive health research, IntellxxDNA™ is proud to announce its IRB approval for the GPS-MEM Study: A Precision Study of Memory.
  • The study will evaluate the efficacy of IntellxxDNA's clinical decision support (CDS) tool.
  • The final goal is to gather feedback from medical practitioners on how significantly the IntellxxDNA™ genomics tool influenced and aided their decision-making process.
  • The study obtained IRB approval on August 16, 2023, with Protocol Number INT-MEM-101 and Approval Number: IRCM-2023-376.

BrainCheck to Showcase Comprehensive Cognitive Health Platform at Hint Summit 2023, the Premier Direct Primary Care (DPC) Innovation Conference

Retrieved on: 
星期二, 九月 19, 2023
Cognition, Partnership, Stanford University, DPC, Ageing, Moca, Marketing, Movement, Dementia, Hint, MSE, Patient, Mini–Mental State Examination, Baylor College of Medicine, Ecosystem, Growth, FDA, Health, Frontier, MMSE, Montreal, Software, Pharmaceutical industry, Nursing, Neuropsychiatry, MD

AUSTIN, Texas, Sept. 19, 2023 /PRNewswire/ -- BrainCheck today announced it will showcase its comprehensive cognitive health platform at Hint Health's Hint Summit event, taking place September 20-23 in San Diego, CA during World Alzheimer's Month and Healthy Aging Month. Attendees are invited to visit the BrainCheck booth #5 to see the company's digital cognitive assessment and care management solutions in action and learn how leading clinicians nationwide are overcoming the limitations of outdated cognitive tests to enhance clinical insights and elevate patient care.

Key Points: 
  • "Following the announcement of our partnership with Hint Health earlier this year, we are thrilled to share our clinically-proven cognitive health platform with the growing direct primary care community at Hint Summit."
  • "With solutions spanning the complete cognitive care continuum, BrainCheck is at the forefront of the cognitive health revolution, enabling earlier detection and personalized intervention for patients," said Zak Holdsworth, CEO and Co-Founder of Hint Health.
  • Ecosystem partners like BrainCheck are integral to this strategy and we're thrilled to highlight the platform at this year's Hint Summit."
  • Hint Health is the leading digital health company dedicated to supporting the growth and success of the DPC movement.

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer's Disease

Retrieved on: 
星期三, 六月 7, 2023
SAB, Houston Methodist Hospital, Clinical Dementia Rating, Alzheimer's disease, Serum, CCL11, CCL2, Alzheimer's Association, PET, IL-6, Brain, Melinda French Gates, Biomarker, Inflammation, Dementia, Trial of the century, COYA, Cerebral cortex, Cognitive Function Scanner, ADAS-Cog, Bill & Melinda Gates Foundation, Patient, Blood, Interleukin 6, Microglia, Cytokine, Mini–Mental State Examination, Therapy, Positron emission tomography, Nerve, MMSE, ALS, Conference, Interleukin, Neuroinflammation, Pharmaceutical industry, Vaccine, Medical imaging, TSPO

- Furthermore, Coya reports a case study of a patient in the COYA 301 trial who had pre-treatment and post-treatment Positron Emission Tomography (PET) brain scans to evaluate neuroinflammation.

Key Points: 
  • - Furthermore, Coya reports a case study of a patient in the COYA 301 trial who had pre-treatment and post-treatment Positron Emission Tomography (PET) brain scans to evaluate neuroinflammation.
  • Meaningful reductions in neuroinflammation were observed throughout the cerebral cortex including hippocampal regions following treatment with COYA 301, which correlated with improvement in cognitive function in this patient.
  • The patients were treated with five day-courses of COYA 301 for four monthly cycles and were followed for two months post-treatment.
  • "We believe these additional data further support our Treg-focused approach to develop safe and effective treatments for neurodegenerative diseases of high unmet need.

NKGen Biotech Presents Interim Phase I Trial Data at 2023 Alzheimer’s Association International Conference

Retrieved on: 
星期一, 七月 17, 2023
Cognition, GFAP, AFL, Week, Disease, Mini–Mental State Examination, NK, Cell, Biomarker, Inflammation, ADAS-Cog, AAIC, Fluid mechanics, Magnetic resonance imaging, Protein, CSF, Poster, Alzheimer's disease, AD, Conference, Expansion, Safety, Pharmaceutical industry, Medical imaging, Patient, MMSE

Subjects received one of three doses of SNK01 (1 x 109 cells, 2 x 109 cells, or 4 x 109 cells).

Key Points: 
  • Subjects received one of three doses of SNK01 (1 x 109 cells, 2 x 109 cells, or 4 x 109 cells).
  • “We are very pleased with the interim results from our Phase I trial,” said Dr. Paul Y.
  • Based on the interim data, no related serious adverse events were observed, and a dose-limiting toxicity was not reached.
  • A SNK01 dose-response was observed, as indicated by cognitive improvement and protein and inflammation markers (CDR-SB, MMSE, pTau181, GFAP and YKL-40).